These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35213032)

  • 21. Scientific and Regulatory Policy Committee Points-to-consider Paper*: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part 2. Antisense Oligonucleotides.
    Engelhardt JA; Fant P; Guionaud S; Henry SP; Leach MW; Louden C; Scicchitano MS; Weaver JL; Zabka TS; Frazier KS;
    Toxicol Pathol; 2015 Oct; 43(7):935-44. PubMed ID: 25717082
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cholesterol-GalNAc Dual Conjugation Strategy for Reducing Renal Distribution of Antisense Oligonucleotides.
    Wada F; Yamamoto T; Ueda T; Sawamura M; Wada S; Harada-Shiba M; Obika S
    Nucleic Acid Ther; 2018 Feb; 28(1):50-57. PubMed ID: 29360004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Localization of unlabeled bepirovirsen antisense oligonucleotide in murine tissues using in situ hybridization and CARS imaging.
    Spencer-Dene B; Mukherjee P; Alex A; Bera K; Tseng WJ; Shi J; Chaney EJ; Spillman DR; Marjanovic M; Miranda E; Boppart SA; Hood SR
    RNA; 2023 Oct; 29(10):1575-1590. PubMed ID: 37460153
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo reduction of hepatitis B virus antigenemia and viremia by antisense oligonucleotides.
    Billioud G; Kruse RL; Carrillo M; Whitten-Bauer C; Gao D; Kim A; Chen L; McCaleb ML; Crosby JR; Hamatake R; Hong Z; Garaigorta U; Swayze E; Bissig KD; Wieland S
    J Hepatol; 2016 Apr; 64(4):781-9. PubMed ID: 26658683
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical Safety Assessment of Therapeutic Oligonucleotides.
    Andersson P
    Methods Mol Biol; 2022; 2434():355-370. PubMed ID: 35213031
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic Toxicity Assessment of 2'-O-Methoxyethyl Antisense Oligonucleotides in Mice.
    Zanardi TA; Kim TW; Shen L; Serota D; Papagiannis C; Park SY; Kim Y; Henry SP
    Nucleic Acid Ther; 2018 Aug; 28(4):233-241. PubMed ID: 29708844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the effect of 2'-O-methyl, fluoro hexitol, bicyclo and Morpholino nucleic acid modifications on potency of GalNAc conjugated antisense oligonucleotides in mice.
    Prakash TP; Yu J; Kinberger GA; Low A; Jackson M; Rigo F; Swayze EE; Seth PP
    Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3774-3779. PubMed ID: 30342955
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the effects of chemically different linkers on hepatic accumulations, cell tropism and gene silencing ability of cholesterol-conjugated antisense oligonucleotides.
    Wada S; Yasuhara H; Wada F; Sawamura M; Waki R; Yamamoto T; Harada-Shiba M; Obika S
    J Control Release; 2016 Mar; 226():57-65. PubMed ID: 26855051
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Co-Administration of an Excipient Oligonucleotide Helps Delineate Pathways of Productive and Nonproductive Uptake of Phosphorothioate Antisense Oligonucleotides in the Liver.
    Donner AJ; Wancewicz EV; Murray HM; Greenlee S; Post N; Bell M; Lima WF; Swayze EE; Seth PP
    Nucleic Acid Ther; 2017 Aug; 27(4):209-220. PubMed ID: 28448194
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluating the Impact of Variable Phosphorothioate Content in Tricyclo-DNA Antisense Oligonucleotides in a Duchenne Muscular Dystrophy Mouse Model.
    Echevarría L; Aupy P; Relizani K; Bestetti T; Griffith G; Blandel F; Komisarski M; Haeberli A; Svinartchouk F; Garcia L; Goyenvalle A
    Nucleic Acid Ther; 2019 Jun; 29(3):148-160. PubMed ID: 31009315
    [TBL] [Abstract][Full Text] [Related]  

  • 31. c-myc antisense oligonucleotide treatment ameliorates murine ARPKD.
    Ricker JL; Mata JE; Iversen PL; Gattone VH
    Kidney Int; 2002 Jan; 61(1 Suppl):S125-31. PubMed ID: 11841626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distribution and biotransformation of therapeutic antisense oligonucleotides and conjugates.
    Weidolf L; Björkbom A; Dahlén A; Elebring M; Gennemark P; Hölttä M; Janzén D; Li X; Andersson S
    Drug Discov Today; 2021 Oct; 26(10):2244-2258. PubMed ID: 33862193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle.
    Prakash TP; Mullick AE; Lee RG; Yu J; Yeh ST; Low A; Chappell AE; Østergaard ME; Murray S; Gaus HJ; Swayze EE; Seth PP
    Nucleic Acids Res; 2019 Jul; 47(12):6029-6044. PubMed ID: 31127296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. miR-182-5p Inhibition Ameliorates Ischemic Acute Kidney Injury.
    Wilflingseder J; Jelencsics K; Bergmeister H; Sunzenauer J; Regele H; Eskandary F; Reindl-Schwaighofer R; Kainz A; Oberbauer R
    Am J Pathol; 2017 Jan; 187(1):70-79. PubMed ID: 27870928
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antisense Oligonucleotide Therapies for Neurodegenerative Diseases.
    Bennett CF; Krainer AR; Cleveland DW
    Annu Rev Neurosci; 2019 Jul; 42():385-406. PubMed ID: 31283897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The future of antisense oligonucleotides in the treatment of respiratory diseases.
    Ulanova M; Schreiber AD; Befus AD
    BioDrugs; 2006; 20(1):1-11. PubMed ID: 16573347
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disarmed anthrax toxin delivers antisense oligonucleotides and siRNA with high efficiency and low toxicity.
    Dyer PDR; Shepherd TR; Gollings AS; Shorter SA; Gorringe-Pattrick MAM; Tang CK; Cattoz BN; Baillie L; Griffiths PC; Richardson SCW
    J Control Release; 2015 Dec; 220(Pt A):316-328. PubMed ID: 26546271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liver as a target for oligonucleotide therapeutics.
    Sehgal A; Vaishnaw A; Fitzgerald K
    J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety, Pharmacokinetic, and Pharmacodynamic Evaluation of a 2'-(2-Methoxyethyl)-D-ribose Antisense Oligonucleotide-Triantenarry
    Zanardi TA; Korbmacher B; Boone L; Engelhardt JA; Wang Y; Burel S; Prill B; Aghajan M; Guo S; Henry SP
    J Pharmacol Exp Ther; 2021 Apr; 377(1):51-63. PubMed ID: 33431610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antisense oligonucleotides as therapeutics for malignant diseases.
    Ho PT; Parkinson DR
    Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.